Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants.
The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT touts pooled analysis of steroid-releasing sinus implants appeared first on MassDevice.
from MassDevice https://ift.tt/2Q5WtCd
Cap comentari:
Publica un comentari a l'entrada